Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Neisseria meningitidis Infections Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Neisseria meningitidis Infections Overview | 11 | 1 |
| Pipeline Products for Neisseria meningitidis Infections Comparative Analysis | 12 | 1 |
| Neisseria meningitidis Infections Therapeutics under Development by Companies | 13 | 1 |
| Neisseria meningitidis Infections Therapeutics under Investigation by Universities/Institutes | 14 | 1 |
| Neisseria meningitidis Infections Pipeline Products Glance | 15 | 3 |
| Late Stage Products | 15 | 1 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Neisseria meningitidis Infections Products under Development by Companies | 18 | 2 |
| Neisseria meningitidis Infections Products under Investigation by Universities/Institutes | 20 | 1 |
| Neisseria meningitidis Infections Companies Involved in Therapeutics Development | 21 | 13 |
| Beijing Minhai Biotechnology Co., Ltd | 21 | 1 |
| Beijing Tiantan Biological Products Co., Ltd. | 22 | 1 |
| Biological E. Limited | 23 | 1 |
| China National Pharmaceutical Group Corporation | 24 | 1 |
| GlaxoSmithKline Plc | 25 | 1 |
| ImmunoBiology Limited | 26 | 1 |
| JN-International Medical Corporation | 27 | 1 |
| MGB Biopharma Limited | 28 | 1 |
| Panacea Biotec Limited | 29 | 1 |
| Pfizer Inc. | 30 | 1 |
| Sanofi Pasteur SA | 31 | 1 |
| Serum Institute of India Limited | 32 | 1 |
| Wellstat Vaccines, LLC | 33 | 1 |
| Neisseria meningitidis Infections Therapeutics Assessment | 34 | 9 |
| Assessment by Monotherapy Products | 34 | 1 |
| Assessment by Combination Products | 35 | 1 |
| Assessment by Target | 36 | 2 |
| Assessment by Mechanism of Action | 38 | 1 |
| Assessment by Route of Administration | 39 | 2 |
| Assessment by Molecule Type | 41 | 2 |
| Drug Profiles | 43 | 45 |
| (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine Drug Profile | 43 | 1 |
| (meningococcal + Haemophilus influenzae [serotype B]) vaccine Drug Profile | 44 | 1 |
| (meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine Drug Profile | 45 | 1 |
| MenBioVax Drug Profile | 46 | 1 |
| meningococcal (tetravalent) vaccine Drug Profile | 47 | 1 |
| meningococcal [serotype B] vaccine Drug Profile | 48 | 4 |
| meningococcal [serotype B] vaccine Drug Profile | 52 | 4 |
| meningococcal [serotype B] vaccine Drug Profile | 56 | 1 |
| meningococcal [serotype B] vaccine Drug Profile | 57 | 1 |
| meningococcal [serotype B] vaccine Drug Profile | 58 | 1 |
| meningococcal [serotype B] vaccine Drug Profile | 59 | 1 |
| meningococcal [serotype B] vaccine Drug Profile | 60 | 1 |
| meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine Drug Profile | 61 | 1 |
| meningococcal [serotypes A, C, W, Y] vaccine Drug Profile | 62 | 1 |
| meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine Drug Profile | 63 | 1 |
| meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine Drug Profile | 64 | 1 |
| meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine Drug Profile | 65 | 1 |
| meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine Drug Profile | 66 | 1 |
| meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine Drug Profile | 67 | 1 |
| meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2 Drug Profile | 68 | 1 |
| meningococcal [serotypes A, C, W-135, Y] vaccine Drug Profile | 69 | 1 |
| meningococcal [serotypes A, C, W-135, Y] vaccine Drug Profile | 70 | 1 |
| meningococcal [serotypes A, C, W135, X, Y] vaccine Drug Profile | 71 | 1 |
| meningococcal [serotypes A, C, W135] vaccine Drug Profile | 72 | 1 |
| meningococcal [serotypes A, C] vaccine Drug Profile | 73 | 1 |
| meningococcal [serotypes C, Y] vaccine Drug Profile | 74 | 1 |
| meningococcal [strain C2135] vaccine Drug Profile | 75 | 1 |
| meningococcal vaccine Drug Profile | 76 | 1 |
| meningococcal vaccine Drug Profile | 77 | 1 |
| meningococcal vaccine 2 Drug Profile | 78 | 1 |
| MGBBP-3 Drug Profile | 79 | 3 |
| Neisseria meningitidis [serotype B] vaccine Drug Profile | 82 | 1 |
| Neisseria meningitidis [serotype B] vaccine Drug Profile | 83 | 1 |
| Nimenrix Drug Profile | 84 | 3 |
| TP-10 Drug Profile | 87 | 1 |
| Neisseria meningitidis Infections Dormant Projects | 88 | 2 |
| Neisseria meningitidis Infections Discontinued Products | 90 | 1 |
| Neisseria meningitidis Infections Product Development Milestones | 91 | 12 |
| Featured News &Press Releases | 91 | 1 |
| Sep 05, 2016: Real world data shows 83 percent effectiveness for Bexsero in infants in first year of UK national meningitis B immunisation programme | 91 | 1 |
| May 20, 2016: Pfizer Announces European Medicines Agency Acceptance For Review Of Marketing Authorization Application For TRUMENBA (Meningococcal Group B Vaccine) | 92 | 1 |
| May 13, 2016: GSK s Bexsero achieves primary and secondary endpoints with reduced 3-dose schedule (2+1) in safety and immunogenicity study in infants and children | 92 | 1 |
| May 13, 2016: Pfizer Presents Results From Two Phase 3 TRUMENBA (Meningococcal Group B Vaccine) Studies At The European Society For Paediatric Infectious Diseases Meeting | 93 | 2 |
| Oct 09, 2015: Pfizer s Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate and Tetanus, Diphtheria and Pertussis Vaccines in Adolescents | 95 | 1 |
| Aug 21, 2015: Pfizer Announces Positive Topline Results Of Two Phase 3 Studies Of TRUMENBA (Meningococcal Group B Vaccine) | 96 | 1 |
| Jun 24, 2015: CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination including TRUMENBA for Adolescents and Young Adults 16 through 23 Years of Age | 97 | 1 |
| Jun 24, 2015: U.S. CDC committee recommends physicians make individual decisions on the use of meningococcal group B vaccines | 97 | 1 |
| May 01, 2015: GSK launches first vaccine to prevent meningococcal disease caused by meningococcus B in Brazil | 98 | 1 |
| Mar 29, 2015: GSK statement on meningitis vaccination in the UK | 98 | 1 |
| Feb 26, 2015: CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk | 99 | 1 |
| Feb 24, 2015: Pfizer Announces Positive Top-line Results Of A Phase 2 Study Of TRUMENBA Co-Administered With Routine Meningococcal (A, C, Y, and W) And Tetanus, Diptheria And Pertussis Vaccines In Adolescents | 100 | 1 |
| Jan 23, 2015: FDA approves a second vaccine to prevent serogroup B meningococcal disease | 101 | 1 |
| Dec 24, 2014: Cansino Biotechnology: Meningococcal Group ACYW135 Quadrivalent Conjugate Vaccine is Approved for Clinical Trial | 102 | 1 |
| Nov 18, 2014: TRUMENBA (Meningococcal Group B Vaccine) is Now Available | 102 | 1 |
| Appendix | 103 | 2 |
| Methodology | 103 | 1 |
| Coverage | 103 | 1 |
| Secondary Research | 103 | 1 |
| Primary Research | 103 | 1 |
| Expert Panel Validation | 103 | 1 |
| Contact Us | 103 | 1 |
| Disclaimer | 104 | 1 |